BOARD OF DIRECTORS
Diarmuid joined the ATXA board as Chairperson in February 2020. Diarmuid has over 26 years of experience in the pharma industry, leading and growing an international pharmaceutical organization. His experience includes the roles of VP; MD; CFO and GM in a multi-billion-euro organization where he has broad ranging experience from establishing and building to divesting businesses. Diarmuid brings strong corporate governance along with expertise in capital expenditure; taxation; regulatory; treasury and risk management across multiple markets and cultures. He held various senior executive management roles at Forest Laboratories in Ireland, UK, Europe, most recently as VP (Europe), Forest Global Healthcare (2010-2015). He is an experienced Pharma/Biotech business strategist and board director, holding a diploma from the Institute of Directors (2011). As an experienced Non-Executive Director, Diarmuid has also contributed widely within the voluntary sector holding board positions in educational, charitable, and sporting organizations.
Prof. Therese Kinsella, PhD, MRIA
Founder, CSO & COO
Therese is a leading expert in the field of prostanoid biology, focusing on the vasculature and, more recently, on cancer. She has published extensively in this area, as the lead author, in top peer-reviewed journals, has extensively patent protected including on the discoveries that underpin ATXA, has acted as an expert CV consultant to both large pharma and life-science venture capital funds. In recognition of her contribution to her research field, she has received a number of awards during her professional career including: in 2000, awarded the Royal Irish Academy Medal in Biochemistry; in 2006, elected as a Member Royal Irish Academy (MRIA); in 2008, awarded the Biochemical Society (IAS) Gold Medal. Having begun her research career in industry (Guinness) as a post-doctoral experimental scientist, Therese has a strong appreciation of the underlying processes of product/drug development, including the associated challenges. She has extensive expertise in securing R&D funding and in company management. As Founder and Chief Executive Officer of ATXA Therapeutics Ltd (ATXA), Therese is the lead inventor on an extensive portfolio of patents based on the discovery of novel Thromboxane Receptor (TP) antagonists in clinical development for treatment of PAH and other clinical indications. Therese also serves as Chief Scientific Officer (CSO) abd Chief Operations Officer (COO) at ATXA.
Daniel O'Mahony, PhD
Board Member / Non-Executive Director
Daniel, a Partner and successful VC investor in pharma & medtech companies at Seroba Life Sciences is a Non-Executive Director of ATXA. Dr. O’Mahony has extensive prior experience in spinning out/working with technologies from universities into start-ups, including Stokes Bio (University Limerick), Apica Cardiovascular (Emory University), PQ ByPass (Fogarty Institute of Innovation, El Camino Hospital, Silicon Valley), Covagen (ETH Zurich), as well as Novate Medical and Atlantic Therapeutics. As a Partner at Seroba, he has invested in various companies which have been acquired, with potential to return over >$500m (between upfront and milestones) to investors including Stokes Bio/Life Technologies, Apica/Thoratec, Covagen/Johnson & Johnson/Janssen and Novate Medical / BTG plc.
Board Member / Non-Executive Director
Jonathan has been employed at senior level in the pharmaceutical industry for more than 20 years, principally in areas of Clinical Development and Medical Affairs. Currently, he is Head of Medical Affairs in Fibrosis at Galapagos NV, (NL). Jonathan also has extensive expertise in the field of Rare Diseases, particularly in respiratory indications including Pulmonary Arterial Hypertension (PAH) where he has more than 15 years’ experience at national and global levels. Prior to joining Galapagos, Jonathan served as the Global Medical Affairs Lead for the Pulmonary Hypertension portfolio at Glaxo Smith Kline (GSK) LTD (NL & UK). While at GSK, he led the late stage PAH clinical development program which included running the successful pivotal Phase III AMBITION clinical trial that demonstrated the importance of use of Ambrisentan and Tadalafil in combination therapy as a first-line treatment for PAH. Prior to this, he has held senior positions at Actelion Pharmaceuticals (UK) and at the Pfizer Pharmaceuticals Group Ltd (London & Kent, UK., and in Tokyo, JP). He has widely published in PAH in leading journals, and brings extensive knowledge of, and experience in, the Pulmonary Hypertension market.